Early response toward clinical remission with dupilumab in severe asthma: Real-world cohort.

Authors

Kenji Mizumura, Yasuhiro Gon, Akihiko Tanaka, Ryosuke Ozoe, Yusuke Kurosawa, Shiho Yamada, Yutaka Kozu, Shuichiro Maruoka, Hironori Sagara, Norihiro Harada, Sumiko Abe, Kazuhisa Takahashi, Taisuke Akamatsu, Toshihiro Shirai, Katsunori Masaki, Koichi Fukunaga, Konomi Kobayashi, Hiroyuki Nagase, Nobuaki Miyahara, Arihiko Kanehiro, Noboru Kitamura, Naruhiko Sugihara, Fumio Kumasawa, Junko Terada-Hirashima, Masayuki Hojo, Kazuyuki Chibana, Mayoko Tsuji, Etsuko Tagaya

Published in

The journal of allergy and clinical immunology. Global. Volume 5. Issue 5. Pages 100749. Epub Jun 12, 2026.

Abstract

Clinical remission is an important treatment goal in severe asthma; however, durable remission frameworks generally require sustained disease control over longer periods. Whether dupilumab induces an early response toward this goal in real-world practice remains unclear.
We sought to evaluate early response toward clinical remission at 24 weeks after dupilumab initiation and to identify baseline factors associated with this outcome.
In this multicenter, prospective cohort at 13 Japanese institutions, adults with severe asthma treated with dupilumab were followed for 24 weeks. Given the limited observation period, an early response toward clinical remission was defined as meeting modified 4-component remission-oriented criteria: Asthma Control Test score 20 or higher, FEV₁ % predicted 80% or higher at week 24, no exacerbations, and no oral corticosteroid use (weeks 16-24). Multivariable logistic regression identified baseline factors associated with this outcome, and receiver-operating characteristic analysis evaluated baseline fractional exhaled nitric oxide (Feno).
Of 103 enrolled patients, 70 had complete data; 38 (54.3%; 95% CI, 41.9%-66.3%) met the modified remission-oriented criteria at week 24. Higher baseline Feno, higher FEV₁ % predicted, and absence of maintenance oral corticosteroid use were associated with this outcome. Baseline Feno showed modest discrimination (area under the curve, 0.65; 95% CI, 0.51-0.78).
Approximately half of the patients met the modified remission-oriented criteria at 24 weeks after dupilumab initiation, representing an early response toward clinical remission rather than sustained clinical remission itself. Baseline Feno and lung function may help identify patients more likely to show this response.

PMID:
42405351
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.